Waters

Waters Corporation surged over 1% to $384.85 during pre-market trading (ET 04:00-09:29) buoyed by FDA 510(k) clearance for its BD BACTEC FXI bloodstream infection diagnostic system, but encountered profit-taking selling during regular session (09:30-15:59), retreating to $376.47 for a modest -0.87% daily decline. This volatile swing reflects initial market enthusiasm over the new diagnostic approval followed by prudent repricing. Additional near-term tailwinds include analyst price target raised to $400 (6.3% upside), Wolfe Research Buy rating, and new mass spectrometry platforms—Xevo MRT P10 and Cyclic IMS P20—expanding its multiomics research portfolio. Yet earnings dynamics present a headwind: Q1 2026 revenue surged 91.39% year-over-year to $1.27 billion but swung to -$72 million net loss with a -5.68% margin, leaving the current 82x PE multiple dependent on significant profit recovery. Positionally, the stock trades 9.1% below its 52-week high of $414.15, suggesting room to recover.